EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Tailored Therapy Guided by Antibiotic Genotypic Resistances and CYP2C19 Polymorphisms Detected From Fecal Specimens for the First‐Line Helicobacter pylori Eradication: A Randomized Controlled Trial

Baojun Suo, Xinlu Ren iD, Cailing Li, Yanyan Shi, Xueli Tian, Kai Zhou, Liya Zhou iD, Zhiqiang Song iD

Helicobacter · 2025

DOI: 10.1111/hel.70082 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Helicobacter, 2025. Verfasst von Baojun Suo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Peking University Third Hospital, Beijing, China. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2C19, Helicobacter Infections, Helicobacter pylori, Anti-Bacterial Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: The Capital's Funds for Health Improvement and Research, the key laboratory for Helicobacter pylori infection and upper gastrointestinal diseases in Beijing, the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tailored therapy based on genetic testing of fecal samples is a promising method for Helicobacter pylori eradication, but relevant research is still lacking, and the effectiveness remains unclear.

Objective

This study conducted a randomized controlled trial to evaluate the efficacy, safety, and compliance of triple plus bismuth therapy (TBT) guided by clarithromycin and levofloxacin genotypic resistances and CYP2C19 polymorphisms from stool samples. A preliminary health economics analysis was also conducted.

Design

Six hundred and sixteen treatment‐naïve patients were randomly divided into tailored (individualized drug selection based on genetic testing for 7 or 14 days) and empiric (esomeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, and bismuth potassium citrate 220 mg, all twice daily for 14 days) TBT groups. Safety and compliance were assessed within 1–3 days after eradication. 13 C‐urea breath test was performed within 4–8 weeks after eradication to evaluate the therapeutic outcome.

Results

The eradication rates of the tailored TBT group were non‐inferior to those of the empiric TBT group [intention‐to‐treat analysis 87.7% vs. 80.8%, rate difference 6.8% (95% confidence interval 0.8%–12.9%); modified intention‐to‐treat analysis 93.4% vs. 86.8%, rate difference 6.7% (95% confidence interval 1.5%–11.9%); per‐protocol analysis 95.7% vs. 88.7%, rate difference 7.0% (95% confidence interval 2.2%–11.8%)]. The tailored TBT group achieved satisfactory efficacies (acceptable in intention‐to‐treat and excellent in per‐protocol analyses). Safety and compliance were similar between the two groups. The average cost of each successful eradication case in the tailored TBT group is lower than that in the empiric TBT group.

Conclusion

The tailored TBT guided by antibiotic genotypic resistances and CYP2C19 polymorphisms detected from fecal specimens achieved satisfactory efficacy, safety, and compliance in the first‐line Helicobacter pylori eradication with less expenses (ChiCTR2300068620). Trial Registration Chinese Clinical Trials Registration: ChiCTR2300068620

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP2C19Helicobacter InfectionsHelicobacter pyloriAnti-Bacterial AgentsFecesDrug Resistance, BacterialPolymorphism, GeneticHumansMaleFemaleMiddle AgedAdultAgedGenotypeTreatment OutcomeDrug Therapy, CombinationPrecision MedicineClarithromycinLevofloxacin

Stichwörter der Autor:innen

Helicobacter pyloriCYP2C19 polymorphismsfecal specimengenotypic resistancetailored therapy

Substanzen

Cytochrome P-450 CYP2C19Anti-Bacterial AgentsCYP2C19 protein, humanClarithromycinLevofloxacin

Autor:innen und Institutionen

  • Department of Gastroenterology, Peking University Third Hospital, Beijing, China.
  • Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China.

ORCID-Profile: Xinlu Ren, Liya Zhou, Zhiqiang Song

Förderung

  • The Capital's Funds for Health Improvement and Research
  • the key laboratory for Helicobacter pylori infection and upper gastrointestinal diseases in Beijing
  • the National Natural Science Foundation of China
  • National Natural Science Foundation of China

Zitieren

APA

Suo, B., Ren, X., Li, C., Shi, Y., Tian, X., Zhou, K., Zhou, L., & Song, Z. (2025). Tailored Therapy Guided by Antibiotic Genotypic Resistances and CYP2C19 Polymorphisms Detected From Fecal Specimens for the First‐Line Helicobacter pylori Eradication: A Randomized Controlled Trial. Helicobacter. https://doi.org/10.1111/hel.70082

Vancouver

Suo B, Ren X, Li C, Shi Y, Tian X, Zhou K, et al. Tailored Therapy Guided by Antibiotic Genotypic Resistances and CYP2C19 Polymorphisms Detected From Fecal Specimens for the First‐Line Helicobacter pylori Eradication: A Randomized Controlled Trial. Helicobacter. 2025. doi:10.1111/hel.70082

BibTeX
@article{Suo2025,
  author = {Suo, Baojun and Ren, Xinlu and Li, Cailing and Shi, Yanyan and Tian, Xueli and Zhou, Kai and Zhou, Liya and Song, Zhiqiang},
  title = {Tailored Therapy Guided by Antibiotic Genotypic Resistances and CYP2C19 Polymorphisms Detected From Fecal Specimens for the First‐Line Helicobacter pylori Eradication: A Randomized Controlled Trial},
  journal = {Helicobacter},
  year = {2025},
  doi = {10.1111/hel.70082}
}
Kostenlos starten →